Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Mons – page 28

640 clinical trials in Mons, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mons at a glance
640
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

640 trials in Mons

Open in trial search

Hypertriglyceridaemia

Not recruiting

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Hypertriglyceridaemia

Not recruiting

Study on the Effects of Pegozafermin and Simvastatin for Patients with Severe High Triglycerides

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:89bio Inc.

Effect of PF-07850327 on Midazolam Pharmacokinetics in Healthy Adult Females (Non‑Childbearing) Relevant to ER+/HER2‑Positive Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Midazolam
  • Sponsor:Pfizer Inc.

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Study on the Safety and Effectiveness of a UTI Vaccine (GSKVX000000046019) for Adults Aged 18-64 and Women Aged 18-64 with Urinary Tract Infections

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:GSKVX000000044501
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Safety and Effects of Trastuzumab Deruxtecan with Drug Combination for Patients with Metastatic HER2-low Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Rheumatoid arthritis

Not recruiting

Study Comparing Abatacept and Tocilizumab for Adults with Rheumatoid Arthritis Not Responding to Previous Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Groupement Des Hopitaux De L'Institut Catholique De Lille

Study of Buparlisib and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Buparlisib
  • Sponsor:Adlai Nortye USA Inc.

B-cell lymphoma+1

Not recruiting

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Mons

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments, including studies of combination therapies with BNT327 and investigations into both small cell and non-small cell variants. Additional research covers breast cancer and cervical cancer treatments.

  • Non-small cell lung cancer therapy optimization
  • Advanced solid tumors treatment
  • Lymphoma treatment innovations

Studies aim to improve survival rates and treatment effectiveness through targeted therapies and immunotherapy combinations.

02 Cardiovascular Studies

Comprehensive research into coronary artery disease and post-stroke treatments, evaluating new antiplatelet therapies and innovative stent technologies. Studies focus on reducing cardiovascular events and improving patient outcomes.

  • Acute coronary syndrome management
  • Stroke prevention strategies
  • Antiplatelet therapy optimization

Investigations aim to enhance treatment protocols and reduce cardiovascular complications.

03 Autoimmune Conditions

Groundbreaking research in multiple sclerosis and psoriatic arthritis treatments, evaluating novel therapeutic approaches including BTK inhibitors and biological treatments.

  • Progressive MS treatment development
  • Arthritis management innovations
  • Long-term therapy effectiveness

Focus on improving quality of life and disease management for patients with chronic autoimmune conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.